Trending 
The US Supreme Court has issued a temporary order that restores the ability to receive the abortion drug mifepristone by mail, effectively lifting a recent ban imposed by a lower court.
This decision ensures that mail access remains available until at least May 11 while the court considers further legal arguments.
The move came after the manufacturer, Danco Laboratories, requested a pause on a ruling from the 5th Circuit Court of Appeals, which had previously mandated that the medication only be obtained in person.
The legal battle stems from a lawsuit initiated by the state of Louisiana against the Food and Drug Administration (FDA).
While the drug has been FDA-approved since 2000 and is used in the majority of American abortions, anti-abortion activists have increasingly challenged its safety.
Despite these challenges, the Supreme Court previously rejected a separate attempt to restrict the drug in 2024, citing a lack of legal standing by the opposing groups.
Currently, mifepristone and misoprostol are approved for use up to 70 days into a pregnancy.
Access to these medications has become a focal point of national debate following the 2022 overturning of Roe v. Wade, which led roughly 20 states to restrict or ban abortion procedures.
While public polling indicates that most Americans support access to safe abortion, conservative organisations continue to pursue legal avenues to limit the availability of these drugs.
